BioXcel Therapeutics (BTAI) Return on Equity (2018 - 2026)

BioXcel Therapeutics' Return on Equity history runs 9 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Equity changed 0.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
• Return on Equity was 0.01% for Q1 2026 at BioXcel Therapeutics, down from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.12% in Q3 2023 to a low of 0.07% in Q2 2023.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.01% in 2025.
• The sharpest annual moves came in 2023 and 2024: Return on Equity increased 13 bps in 2023, then fell 11 bps in 2024.
• A 5-year view of Return on Equity shows it stood at 0.02% in 2022, then jumped by 326 bps to 0.04% in 2023, then slumped by 76 bps to 0.01% in 2024, then decreased by 19 bps to 0.01% in 2025, then fell by 8 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.